Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Net Sales has grown by an annual rate of 0% and Operating profit at -5.13% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
ILS 298 Million ()
NA (Loss Making)
NA
0.00%
-0.32
1,640.18%
-177.80
Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2024)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
107.5%
0%
107.5%
6 Months
107.5%
0%
107.5%
1 Year
93.62%
0%
93.62%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Bonus Biogroup Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-5.13%
EBIT to Interest (avg)
-20.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.75
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
40.79
EV to EBIT
-10.15
EV to EBITDA
-10.99
EV to Capital Employed
158.57
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1562.44%
ROE (Latest)
-394.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.90
-6.80
27.94%
Interest
0.20
0.70
-71.43%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.90
-7.50
21.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in quarter ended Dec 2024 is 21.33% vs 25.00% in Dec 2023
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-23.40
-25.60
8.59%
Interest
0.80
0.90
-11.11%
Exceptional Items
-1.60
-1.40
-14.29%
Consolidate Net Profit
-27.80
-28.50
2.46%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 2.46% vs 26.36% in Dec 2023






